Know Cancer

or
forgot password

Observational Study of Immune Responses in Prostate Cancer Patients Following Stereotactic Body Radiotherapy (SBRT)


N/A
18 Years
N/A
Open (Enrolling)
Male
Oligometastatic Prostate Cancer

Thank you

Trial Information

Observational Study of Immune Responses in Prostate Cancer Patients Following Stereotactic Body Radiotherapy (SBRT)


Inclusion Criteria:



- Oligometastatic prostate cancer patients with < 4 metastatic lesions that are
amenable to Stereotactic Body Radiotherapy (SBRT)

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Induction of anti-prostate cancer immunity

Outcome Time Frame:

Before, during and after Stereotactic Body Radiotherapy (SBRT)

Safety Issue:

No

Principal Investigator

Sean S Park, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mayo Clinic

Authority:

United States: Institutional Review Board

Study ID:

12-008383

NCT ID:

NCT01777802

Start Date:

January 2013

Completion Date:

June 2015

Related Keywords:

  • Oligometastatic Prostate Cancer
  • Prostatic Neoplasms

Name

Location

Mayo Clinic in RochesterRochester, Minnesota  55905